Idiopathic thrombocytopenic purpura (ITP)
Also known as: Idiopathic thrombocytopenic purpura
Methodology & AI Transparency ⓘ
Idiopathic thrombocytopenic purpura (ITP) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code D69.6 in Blood & Anemia, Idiopathic thrombocytopenic purpura (ITP) (also termed Idiopathic thrombocytopenic purpura) requires targeted oral/IV iron in Idiopathic thrombocytopenic purpura (ITP) (D69.6: or vitamin repletion) so specialists can calibrate treatment intensity against Serum Ferritin & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: Transferrin Saturation) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry D69.6: Idiopathic thrombocytopenic purpura (ITP) is managed within Blood & Anemia (aka Idiopathic thrombocytopenic purpura).
- 3 Typical cash cost range: Workup highlights for Idiopathic thrombocytopenic purpura (ITP) (D69.6): targeted oral/IV iron in Idiopathic thrombocytopenic purpura (ITP) (D69.6: or vitamin repletion).
- 4 Top reported side effects / signs: Objective lab/clinical target for Idiopathic thrombocytopenic purpura (ITP): Serum Ferritin & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: Transferrin Saturation) (Ferritin 50–150 ng/mL; TSAT 20%–45% (D69.6)) and Vitamin B12, Folate in Idiopathic thrombocytopenic purpura (ITP) (D69.6: & Reticulocyte Count).
Ask our AI Specialists anything about Idiopathic thrombocytopenic purpura (ITP)
What Is Idiopathic thrombocytopenic purpura (ITP)?
Cataloged under federal diagnostic code D69.6 in Blood & Anemia, Idiopathic thrombocytopenic purpura (ITP) (also termed Idiopathic thrombocytopenic purpura) requires targeted oral/IV iron in Idiopathic thrombocytopenic purpura (ITP) (D69.6: or vitamin repletion) so specialists can calibrate treatment intensity against Serum Ferritin & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: Transferrin Saturation) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in blood & anemia, Idiopathic thrombocytopenic purpura (ITP) (D69.6) involves primary platelet/megakaryocyte dysregulation in Idiopathic thrombocytopenic purpura (ITP) (D69.6: or inherited/acquired coagulation). progression correlates with shifts in Serum Ferritin & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: Transferrin Saturation) (Ferritin 50–150 ng/mL; TSAT 20%–45% (D69.6)).
Common Symptoms & Clinical Signs
- • Presentation of Idiopathic thrombocytopenic purpura (ITP) (D69.6): restless legs, ice in Idiopathic thrombocytopenic purpura (ITP) (D69.6: craving)
- • Secondary Idiopathic thrombocytopenic purpura (ITP) clinical sign: easy bruising, prolonged in Idiopathic thrombocytopenic purpura (ITP) (D69.6: bleeding from minor)
- • Symptom flares in Idiopathic thrombocytopenic purpura (ITP) correlating with Serum Ferritin & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: Transferrin Saturation) deviation outside Ferritin 50–150 ng/mL; TSAT 20%–45% (D69.6)
- • Functional blood & anemia impact requiring targeted oral/IV iron in Idiopathic thrombocytopenic purpura (ITP) (D69.6: or vitamin repletion) evaluation (D69.6)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Idiopathic thrombocytopenic purpura (ITP) Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D69.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Anemia, Clotting & Blood Disorders | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Ferritin & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: Transferrin Saturation) | Ferritin 50–150 ng/mL; TSAT 20%–45% (D69.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Vitamin B12, Folate in Idiopathic thrombocytopenic purpura (ITP) (D69.6: & Reticulocyte Count) | B12 > 500 pg/mL; appropriate marrow response (D69.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Platelet Count & in Idiopathic thrombocytopenic purpura (ITP) (D69.6: PT/INR / aPTT) | Platelets 150–400 x10^3/uL (D69.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Idiopathic thrombocytopenic purpura (ITP)
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Trihexyphenidyl Hydrochloride Artane • RxCUI 905269 | Parkinson's Disease Agent | 77% | $0.0722 | $ 6.88 /mo |
| Levocetirizine Dihydrochloride Allergy Relief 24hr, Allergy Relief • RxCUI 855172 | Histamine-1 Receptor Antagonist | 88% | $0.0511 | $ 5.96 /mo |
| Prucalopride Motegrity • RxCUI 2107345 | Serotonin-4 Receptor Agonist | 85% | $0.6336 | $ 12.25 /mo |
| Lubiprostone Amitza, Amitiza • RxCUI 616578 | Chloride Channel Activator | 82% | $0.5493 | $ 10.87 /mo |
| Carbidopa Lodosyn • RxCUI 260260 | Aromatic Amino Acid Decarboxylation Inhibitor | 79% | $0.5325 | $ 13.63 /mo |
| Pirfenidone Esbriet • RxCUI 1868014 | Pyridone | 74% | $0.6527 | $ 21.95 /mo |
| Plecanatide Trulance Immediate Release, Trulance • RxCUI 1873757 | Guanylate Cyclase-C Agonist | 86% | $1.5000 | $ 69.25 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Idiopathic thrombocytopenic purpura (ITP))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Influence of Demographic Factors on Clinical Outcomes in Adults With Chronic: What a 2,639-Participant Study Found Overall (N = 2,639; 3 mg of plecanatide [n = 877]; 6 mg of plecanatide [n = 877]; and placebo [n = 885]), CSBM responder rates were significantly greater with 3 mg of plecanatide and 6 mg of plecanatide vs placebo in subgroups... Clinical and translational gastroenterology • 2023-07-01 • Phase III Randomized Trial | N = 2,639 | 96/100 | PMID 37162147 ↗ |
| Can This Approach Help? Inside the Latest Research on Low-sodium oxybate on diary-based sleep time in a clinical study in adults with Open-label LXB treatment in adults with idiopathic hypersomnia was associated with reductions in 24-hour TST, nocturnal TST, and total nap duration. Sleep medicine • 2026-02-15 • Phase III Randomized Trial | N = 148 | 88/100 | PMID 41442817 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits of finasteride for hirsute women with polycystic ovary syndrome or All the patients treated with finasteride perceived a reduction in hirsutism after 6 months. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology • 2003-02-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 12724020 ↗ |
| New Insights on Serum biomarkers associated with baricitinib response in patients with juvenile: What a 220-Participant Study Found To our knowledge, this is the first study measuring serum protein markers in the context of an intervention trial with baricitinib in patients with JIA. The Lancet. Rheumatology • 2025-11-15 • Phase III Randomized Trial | N = 220 | 88/100 | PMID 40915298 ↗ |
| Can This Approach Help? Inside the Latest Research on A minimal clinically important difference for the sleep inertia visual analog Establishing an MCID strengthens the SI-VAS value, adds context for findings related to sleep inertia in individuals with idiopathic hypersomnia from the phase 3 study, and aids clinicians in identifying clinically meaningful... Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine • 2025-07-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 40135693 ↗ |
Idiopathic thrombocytopenic purpura (ITP) Patient Community & “People Like Me” Threads
Filter Idiopathic thrombocytopenic purpura (ITP) community threads and patient logs by age, biological sex, dosage, and treatment duration.